US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% SDEV $7.48 ▲+0.00% WDC $415.29 ▲+0.00%
FinancialContent

Articles published by Polyrizon Ltd.

< Previous 1 2 Next >
News headline image
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Regains Compliance with Nasdaq Listing Requirements
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Retains Nasdaq Listing Following Hearings Panel
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Announces Receipt of Nasdaq Delisting Notice
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Ltd. Announces $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
News headline image
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
< Previous 1 2 Next >